Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. van Besien K, et al. Among authors: rich e. Biol Blood Marrow Transplant. 2012 Jun;18(6):913-21. doi: 10.1016/j.bbmt.2011.10.041. Epub 2011 Nov 9. Biol Blood Marrow Transplant. 2012. PMID: 22079470 Free PMC article. Clinical Trial.
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Artz AS, et al. Among authors: rich e. Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64. doi: 10.1016/j.bbmt.2006.05.015. Biol Blood Marrow Transplant. 2006. PMID: 16920562 Free article. Clinical Trial.
Chimerism does not predict for outcome after alemtuzumab based conditioning.
Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K. Michaelis L, et al. Among authors: rich e. Bone Marrow Transplant. 2007 Jul;40(2):181. doi: 10.1038/sj.bmt.1705707. Epub 2007 May 14. Bone Marrow Transplant. 2007. PMID: 17502895 No abstract available.
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Pollyea DA, et al. Among authors: rich e. Bone Marrow Transplant. 2007 Dec;40(11):1027-32. doi: 10.1038/sj.bmt.1705852. Epub 2007 Sep 10. Bone Marrow Transplant. 2007. PMID: 17846595 Clinical Trial.
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Gordon MK, et al. Among authors: rich e. Leuk Lymphoma. 2008 Mar;49(3):531-7. doi: 10.1080/10428190701799043. Leuk Lymphoma. 2008. PMID: 18297531
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. Stock W, et al. Among authors: rich e. Invest New Drugs. 2008 Aug;26(4):331-8. doi: 10.1007/s10637-008-9129-0. Epub 2008 Apr 19. Invest New Drugs. 2008. PMID: 18425419 Free PMC article. Clinical Trial.
434 results